Mirati Therapeutics. has filed a patent for compounds that inhibit KRas G12D activity. The invention includes specific compounds, pharmaceutical compositions, and methods of use. GlobalData’s report on Mirati Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Mirati Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Mirati Therapeutics's grant share as of January 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
The patent application (Publication Number: US20240034733A1) discloses a series of compounds represented by Formula (I) and their salts, with specific variations outlined in subsequent claims. These compounds are designed to inhibit KRas G12D activity in cells, making them potentially valuable in cancer treatment. The compounds can be administered as pharmaceutical compositions with suitable excipients. The methods described involve contacting cells with the compound to inhibit KRas G12D activity or administering the compound to patients with cancer, particularly those with KRas G12D-associated cancers such as non-small cell lung cancer, small cell lung cancer, colorectal cancer, rectal cancer, or pancreatic cancer.
Furthermore, the patent application details the specific structures and substitutions of the compounds, such as R1 being hexahydro-1H-pyrrolizinyl or pyrrolidine, and R2 forming different ring systems. The compounds can also have various substituents on R3, R5, R6, and R7, providing flexibility in their design. The methods for treating cancer involve determining the presence of a KRas G12D mutation in the cancer cells and administering the compound in therapeutically effective amounts, typically ranging from 0.01 to 100 mg/kg per day. Overall, the patent application presents a comprehensive approach to developing compounds for inhibiting KRas G12D activity and treating various types of cancer, particularly those associated with the specified mutation.
To know more about GlobalData’s detailed insights on Mirati Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
